The review for IOA began on 23 December 2009 with an active review time of 210 days.The Committee gave also a positive opinion for Cinryze (C1 inhibitor, human), an orphan medicine from ViroPharma ...

The opinion will now be referred to the European Commission for final regulatory decision on donanemab  INDIANAPOLIS, July 25 ...

Novo Nordisk (NYSE:NVO) is one of the most profitable value stocks to buy according to analysts. On July 25, Novo Nordisk ...

Kisunla’s active substance is donanemab, a monoclonal antibody that targets and clears amyloid-beta plaques in the brain, a ...

"Gilead wins positive European approval opinion for twice-yearly HIV injection" was originally created and published by ...

PR Newswire Fri, Feb 28, 2025, 8:23 AM9 min read ...

Meeting Highlights from the Committee for Medicinal Products for Human Use, 17-20 September 2007 Positive opinions LONDON, Sept. 21, 2007--The European Medicines Agency’s (EMEA) Committee for ...

The review for IOA began on 23 December 2009 with an active review time of 210 days.The Committee gave also a positive opinion for Cinryze (C1 inhibitor, human), an orphan medicine from ViroPharma ...

The Committee for Medicinal Products for Human Use (CHMP) reaffirms positive opinion for Lecanemab in early Alzheimer's disease in the EU Provided by PR Newswire Feb 28, 2025 5:11am ...

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has reaffirmed ...

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP), 15-18 November 2010Positive opinion for a new medicine adoptedThe Committee adopted a positive opinion recommending ...